Stay updated with breaking news from Cell Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jefferies Financial Group lowered shares of Terumo (OTCMKTS:TRUMY – Free Report) from a buy rating to a hold rating in a research note published on Monday, FlyOnTheWall reports. Terumo Trading Down 2.6 % Shares of OTCMKTS:TRUMY opened at $27.87 on Monday. Terumo has a 52-week low of $25.59 and a 52-week high of $34.65. The […]
Terumo Blood and Cell Technologies (Terumo BCT) announces US Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the US that processes whole blood into platelets and other components in a single centrifugation cycle ...
The Australian share market shed 0.7% in Friday trade as the Bank of Japan shook up markets with a pledge to be more flexible in managing interest rates.
London, July 7, - Behind every accomplished business, there is an influential and dignified chief executive officer (CEO) that has an impact on the econ...
Terumo Co. (OTCMKTS:TRUMY – Free Report) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 13,900 shares, a growth of 44.8% from the May 31st total of 9,600 shares. Based on an average daily trading volume, of 44,400 shares, the […]